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Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome 
which results in uncontrolled systemic proliferation of benign macrophages in all 
reticuloendothelial organs producing worsening peripheral blood cytopenia(s); 
hypercytokinemia leading to hepatic injury producing hyperferritinemia, hyper-
triglyceridemia, hypofibrinogenemia; and if not diagnosed and treated early may 
lead to disseminated intravascular coagulation (DIC), multiorgan dysfunction, 
and death in nearly all individuals. It is postulated that hepatic injury/dysfunction 
starts early in the course of the disease which may mimic nonspecific hepatitis like 
prodrome to fulminant hepatic failure; possibly requiring liver transplant. While 
HLH as an entity is being increasingly recognized nowadays across wide specialties 
(both pediatric and adults); hepatic involvement in this setting has been poorly 
characterized. This chapter is aimed to highlight on the diagnosis and classification 
of HLH with a special emphasis on the pathophysiology of hepatic dysfunction, 
histomorphology of liver; and the current concept and controversies on the role of 
liver transplantation in this clinical setting.
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1. Introduction
Hemophagocytic lymphohistiocytosis (HLH) or hemophagocytic syndrome is 
a potentially catastrophic hyperinflammatory syndrome occurring in genetically 
susceptible individuals which results due to hyperactive, yet inappropriate, immune 
system going runamock [1]. This results due to impaired cytotoxic T lymphocyte 
(CTL)/natural killer (NK) cell activity producing uncontrolled proliferation of benign 
macrophages in all reticuloendothelial organs such as bone marrow, spleen, liver, 
and lymph nodes; causing histiocytic hemophagocytosis, worsening unexplained 
peripheral blood cytopenia (s), cytokine storm, cytokine mediated hepatic injury/
dysfunction producing spectrum of biochemical alteration such as hyperferritinemia, 
hypertriglyceridemia, hypofibrinogenemia, coagulopathy, disseminated intravascular 
coagulation (DIC), multi organ dysfunction (MOD); and if not diagnosed and treated 
early, may lead to death in virtually all case [2]. Since the first description of cases 
coined as “histiocytic medullary reticulocytosis” by Scott Robin and Smith in 1939, 
there has been a sequential change in nomenclature of this entity [3–6]. While HLH 
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as an entity is being increasingly recognized nowadays across wide specialties (both 
pediatric and adults); hepatic involvement in this setting has been poorly charac-
terized [7–9]. Hepatomegaly and hepatic dysfunction, including elevated serum 
transaminases and bilirubin, cholestasis, and coagulopathy typically occur early in the 
disease and are associated with marked hematologic and/or neurological abnormali-
ties. In rare instances acute hepatic failure may dominate the clinical picture, which in 
combination with hyperferritinemia, may mimic neonatal hemochromatosis [10].
2. Classification of HLH
Traditionally, HLH has been broadly classified into two forms: (i) primary HLH 
which is known to harbor documented genetic abnormalities implicated in the 
cytotoxic functions of the NK cell/CTL; and (ii) a secondary form which occurs 
in adults/elderly population without any genetic abnormality. However, upon the 
realization that HLH defining genetic abnormality can occur in any age, that these 
defects may be uncommon even in pediatric age group, the designations primary and 
secondary have become less relevant; and stratification into genetic and acquired forms 
seems more appropriate [11]. The genetic variant is again subdivided into autosomal 
recessive familial HLH (FHL) involving the several mutations in the CTL/NK  
Type Examples with proportions in parentheses
A. Genetic
i. Autosomal recessive/familial HLH PFR1/perforin 1 (20-50%), UNC13D/Munc 13-4 (20%), 
STX11/syntaxin 11 (1%), STXB2/syntaxin binding protein 2 
or UNC18B (unknown)
ii. Associated with primary 
immunodeficiency syndromes
Chediak-Higashi syndrome (LYST), Griscelli syndrome type 
2 (RAB27A/Rab27a), Hermansky-Pudlak syndrome type 
2 (AP3B1), X-linked proliferative syndrome (XLP) type 1 
(SHD2D1A/SAP protein), X-linked proliferative syndrome 
(XLP) type 2 (BIRC4/XIAP protein)
B.Acquired
i. Virus associated Herpes viruses (EBV, CMV, HHV-8, HSV), HIV, HTLV, 
adenovirus, HAV, HBV, HCV, measles, mumps, rubella, 
dengue, hantavirus, parvovirus B19, Enterovirus, influenza
ii. Bacteria associated Staphylococcus aureus, Campylobacter spp., Fusobacterium spp., 
Mycoplasma spp., Chlamydia spp., Legionella spp., Salmonella 
typhi, Rickettsia spp., Brucella spp., Ehrlichia spp., Borrelia 
burgdorferi, Mycobacterium tuberculosis
iii. Fungal associated Candida spp., Cryptococcus spp., Pneumocystis spp., 
Histoplasma spp., Aspergillus spp., Fusarium spp.
iv. Parasitic Plasmodium falciparum, Plasmodium vivax, Toxoplasma spp., 
Babesia spp., Strongyloides spp., Leishmania spp.
v. Malignancy associated Peripheral T-cell/NK-cell lymphomas, ALCL, ALL, Hodgkin 
lymphoma, multiple myeloma, acute erythroid leukemia
Prostate and lung cancer, hepatocellular carcinoma
vi. Autoimmune disease associated 
(macrophage activation syndrome, 
MAS)
Systemic-onset juvenile idiopathic arthritis, Kawasaki 
disease, systemic lupus erythematosus, seronegative
spondyloarthropathies
Table 1. 
Classification of hemophagocytic lymphohistiocytosis (HLH) (adopted from Rosado et al. [1] and 
Gholam et al. [12]).
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cell cytotoxic pathways [PFR1/perforin 1 (20–50%), UNC13D/Munc 13-4 (20%), 
STX11/syntaxin 11 (1%), STXB2/syntaxin binding protein 2 or UNC18B (unknown)] 
and those associated with primary immunodeficiency syndromes such as Chédiak-
Higashi syndrome (LYST), Griscelli syndrome type 2 (RAB27A/Rab27a), Hermansky-
Pudlak syndrome type 2 (AP3B1), and X-linked proliferative syndrome (XLP) type 1 
(SHD2D1A/SAP protein) and type 2 (BIRC4/XIAP protein) [12] (Table 1).
Acquired form of HLH is known to be triggered by diverse etiologies in suscep-
tible individuals; and are segregated as (i) infection associated secondary to viruses 
(notably EVB, CMV, HHV-8, HSV, dengue, parvo B19, HAV, HBV, HCV, etc.; any 
bacteria, fungi, parasites such as Plasmodia, Leishmania, Strongyloides),  
(ii) malignancy associated (NK-T cell lymphoma/leukemia, anaplastic large 
cell lymphoma, plasma cell myeloma, Hodgkin lymphoma, B cell non Hodgkin 
lymphoma, acute lymphoid and myeloid leukemias; and solid malignancies such 
as lung cancer, hepatocellular carcinoma, etc.), and (iii) macrophage activation 
syndrome or MAS (associated with autoimmune disorders) [1, 3, 13].
3. Diagnostic criteria
There has been a paradigm shift of focus in the diagnosis of HLH since 2004 
(Table 2) [3]. The 2004 diagnostic criteria developed for the pediatric HLH have been 
widely adopted in adult medicine without systematic validation. Both 2004 and 2009 
guidelines incorporated mutational/genetic analysis as a “major criterion” which has 
subsequently been taken out, especially for adult HLH case. Moreover, two important 
parameters that were incorporated in previous criteria such as “impaired NK cell activ-
ity” and “increased soluble interleukin 2 receptor” are likely to be removed sooner or 
later as these tests are available in only very few specialized centers all over the world 
and are very costly. Therefore, in practice, the necessary five out of eight criteria as per 
the HLH 2004 guidelines are actually five out of six parameters tested. In addition, the 
criteria of “bone marrow hemophagocytosis” is becoming increasingly less important 
nowadays as histiocytic hemophagocytosis has a poor specificity in the diagnosis 
of HLH and this may not even be evident during initial marrow evaluation [1]! In 
order to overcome these shortcomings, the French investigators proposed to adopt a 
new objective scoring system (HLH probability score or HScore) (Table 3). A total 
probability score of 169 was found to have a higher sensitivity and specificity for the 
diagnosis of HLH [6]. Furthermore, simpler routine laboratory parameters (extended 
variables) have been incorporated to diagnose the disease early. These include periph-
eral blood monocytosis, hyponatremia, elevated lactate dehydrogenase, elevated β2 
microglobulin, impaired coagulation parameters, and CSF pleocytosis [14].
Another interesting change has been made in regard to the measurement of 
serum ferritin. A ≥ 500 μg/L cut off among pediatric population (up to 18 years 
of age) was found to have 84% sensitivity in HLH-1994 trial and therefore was 
included in the HLH 2004 guidelines [15]. Subsequently, pediatricians have revised 
their ferritin cut off value to ≥10,000 μg/L with a higher sensitivity and near 100% 
specificity for the diagnosis of HLH [16]. On the contrary, recent reports from adult 
intensive care units (ICUs) have suggested a lower ferritin cut off value of 3000 
to 4000 μg/L with >80% sensitivity and specificity in HLH diagnosis [17]. While 
hyperferritinemia is not specific to HLH, the same in the clinical context of fever, 
worsening cytopenia (s), and splenomegaly is highly valuable in the ICUs where 
sepsis is the major overlapping clinical condition [18]. Recent studies have shown 
that a high serum soluble interleukin 2 receptor to ferritin ratio is an important 
biomarker in distinguishing lymphoma associated HLH compared to benign disease 
associated HLH (8.56 vs. 0.66, respectively, P = 0.0004) [19].
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4. Pathophysiology of HLH
Genetic HLH results due to inability to clear the antigenic stimulus and thus turn 
off the inflammatory response is what ultimately leads to cytokine storm character-
istic of HLH. In healthy individuals, viral and tumor antigenic stimuli leads to Th1 
mediated cytokine response (IFN-γ, TNF-α, GM-CSF) which in turn, stimulates 
CTL and NK cells to clear off target cells (viral infected cells, tumor cells, etc.) 
through release of perforin and granzyme granules at the synaptic site. Perforin is a 
key cytolytic protein that acts by inserting itself in the membrane of the target cell 
and creating pores that lead to osmotic lysis of the target cell. The normal produc-
tion of vesicle granule content requires orchestrated steps of maturation, polariza-
tion, docking, fusion, and finally degranulation in the immunological synapse. All 
the genetic defects described in FHL involve either inadequate levels of perforin 
itself (FHL2) or improper granule exocytosis (FHL3–5 and immunodeficiency 
syndromes) (see above in the classification) (Figure 1) [2, 20].













Molecular diagnosis x x √ √ x x
Immunosuppression 
(Table 3)
x x x x √ x
Fever √ √ √ √ √ √
Splenomegaly √ √ √ √ √ √
Cytopenia (s)¶ √ √ √ √ √ √
Hyperferritinemia¶¶ x x √ √ √ √
Hypertriglyceridemia¶¶¶ √ √ √ √ √ √
Hypofibrinogenemia≠ √ √ √ √ √ √
Hemophagocytosis √ √ √ √ √ √§
Decreased NK cell 
activity§§
x x √ √ x x
Increased soluble IL2 
receptor§§
x x √ √ x x
Raised SGOT x x x x √ x
Required number of 
criteria












Supportive featuresǁ x x x x √ √
¶Hemoglobin; <90 g/L (in infants <4 weeks old, <100 g/L); Platelets <100 × 109/L; Neutrophils <1.0 × 109/L).
¶¶≥ 500 μg/L.
¶¶¶Fasting triglycerides ≥3.0 mmol/L (≥265 mg/dL).
≠≤1.5 g/L.
§In bone marrow aspirate.
§§Likely to be dropped as a criteria.
ǁCoagulopathy, hyperbilirubinemia, hypoalbuminemia, hyponatremia, raised lactate dehydrogenase, elevated β2 
microglobulin, peripheral blood monocytosis, CSF pleocytosis, etc.
√ Included in the criteria. x Not included in the criteria.
Table 2. 
Updated diagnostic criteria for HLH [3–6, 14].
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5. Pathophysiology of hepatic dysfunction: the cytokine theory
It is now postulated that hepatic injury/dysfunction HLH is mainly due to 
cytokine storm which results due to impaired NK/Cytotoxic T lymphocyte function 
in a genetically susceptible individual while triggering factors playing a crucial role. 
The up regulation of granulocytic monocytic colony stimulating factor receptor 
on the macrophages along with macrophage proliferation leads to splenohepato-
megaly. The macrophage derived IL-2, IFN-γ, and TNF-α mediated inflammation 
is reported to be predominantly porto-sinusoidal rather than lobular without any 
significant alteration in lobular architecture; which in turn produces raised trans-
aminases, hepatocyte hemosiderosis; sinusoidal dilatation and congestion, Kupffer 
cell hyperplasia and hypertrophy producing hemosiderosis and hemophagocytosis. 
Furthermore, lymphocyte or lymphohistiocyte mediated biliary ductular injury 
Parameters Number of points (criteria for scoring)
Known immunosuppression¶ 0 (no) or 18 (yes)
Temperature (°C) 0 (<38.4), 33 (38.4-39.4), or 49 (>39.4)
Organomegaly 0 (no), 23 (hepatomegaly or splenomegaly), or 38 (hepatomegaly 
and splenomegaly
Number of cytopenia (s)± 0 (1 lineage), 24 (2 lineages), or 34 (3 lineages)
Ferritin (μg/L) 0 (< 2000), 35 (2000–6000), or 50 (>6000)
Triglyceride (mmoles/L) 0 (<1.5), 44 (1.5–4), or 64 (>4)
Fibrinogen (g/L) 0 (>2.5), or 30 (≤ 2.5)
Serum SGOT (IU/L) 0 (< 30), or 19 (≥ 30)
Hemophagocytosis in marrow 
aspirate
0 (no) or 35 (yes)
¶Human immunodeficiency virus or receiving long term immunosuppressive therapy (glucocorticoids, cyclosporine, 
azathioprine).
±Hb ≤ 92 g/L, total leukocyte count ≤ 5000/mm3, platelet count ≤ 110,000/mm3.
Table 3. 
Hemophagocytic lymphohistiocytosis probability score (HScore) as proposed by Fardet et al. [6].
Figure 1. 
Immune response in healthy subjects and uncontrolled, ineffective immune response in patients with genetic 
HLH. Adopted and modified from Janka GE [2].
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and cytokine (IL 1, IL 6, and TNF-α) mediated impaired lipoprotein lipase activity 
causes cholestasis, hyperbilirubinemia and hypertriglyceridemia. Finally, hyperfer-
ritinemia so characteristic of HLH, is nothing but the result of acute phase reaction 
as well as increased erythrophagocytosis by Kupffer cells. All these cytokine basis 
of hepatic injury may culminate in severe hepatic functional compromise leading to 
hypofibrinogenemia, hypoalbuminemia, disseminated intravascular coagulation, 
and multiorgan dysfunction with a fatal outcome (Figure 2).
6. Histology of liver in HLH
The morphology of liver in HLH is not well characterized because of insuf-
ficient biopsy data, late diagnosis, sampling bias (needle biopsy vs. wedge biopsy); 
and associated triggering factors such as virus associated histological alterations; 
especially in acquired cases (Table 4).
Morphological changes as observed in several large series of liver biopsy speci-
mens have shown relatively well-preserved hepatic parenchyma with a portal and 
sinusoidal lymphohistiocytic, CD 3+, CD8+, Granzyme B+, and variable perforin+ T 
cell-rich infiltrate [7–9, 21, 22]. Diverse histological patterns have been described in 
such cases (Table 4): (i) adult type chronic hepatitis like characterized by mild portal 
lymphocytic infiltrate with mild bile duct injury and endothelialitis, reported to be 
so characteristic of neonatal/childhood HLH; (ii) leukemia like pattern characterized 
by extensive portal, lymphohistiocytic infiltrate expanding the tracts and encroaching 
upon the lobular periphery blurring the portal limiting plate and infiltrating the sinu-
soids; (iii) histiocytic storage disorder-like pattern characterized by massive infiltration 
of histiocyte rich infiltrate plugging and distending the sinusoids and venules; (iv) 
neonatal giant cell hepatitis-like pattern characterized by extensive giant cell transfor-
mation of hepatocytes with prominent architectural disarray; (v) increased hepatic 
hemosiderosis along with marked hyperferritinemia and features of acute liver 
failure mimicking neonatal hemochromatosis; (vi) post stem cell transplantation graft 
Figure 2. 
Cytokine basis of HLH associated hepatic dysfunction. GM-CSF; granulocytic monocytic colony stimulating 
factor, IL; interleukin, IFN-γ; interferon gamma, TNF-α; tumor necrosis factor alpha, DIC; disseminated 
intravascular coagulation, MODS; multiorgan dysfunction syndrome. Note the parameters from no. 1 to 7 
are incorporated in the HLH criteria. The pathophysiologic features assigned A to D are related to cytokine 
mediated liver parenchymal alteration (see below). Schematic representation summarized from de Kerguenec 
























mediated bile duct 











1. 12d, M All Present; Severe, lobular 
>> portal, Giant cell 
hepatitis like, spotty 
necrosis




Yes/LH type ↑/x +++ Yes Death
2. 7m, M All Absent; Moderate to 
severe, centrilobular 
hepatitis, chronic active 
GVHD
++/x +, fibrosis, 
Perforin+ T cells
Yes/lymphocytic ↑/+ Mild No Death
3. 16d, M All Present; lobular 
>> portal, Giant 
cell hepatitis like, 








Yes/LH type ↑/+++ +++ Yes Death
4. 25d, - ALF Absent; Portal >> 
lobules; centrilobular 
necrosis
+++ +++, leukemia 
like, CD8/Gr. B/
Perforin+
Yes/dense lymphocytic ↑/x +++ Yes, Congestion
5. 2m, M ARF Absent; Portal >> 
lobules




Yes/lymphocytic ↑/+ +++ Yes Death
6.2m, F All Absent; Portal >> 
lobules
+/++ +++; leukemia like; 
Perforin+ T cells























mediated bile duct 











7. 2m, M All Absent; Portal >> 
lobules, hemosiderosis 
(+)
++/x +++; leukemia 
like; CD8/Gr B/
Perforin+ T cells
Yes/LH type ↑/+ + Yes Death
8. 3m, M All Absent; lobular >> 
portal, chronic hepatitis 
like
+++/+ +; chronic persistent 
hepatitis like; CD8/
Gr B+/Perforin−  
T cells
Yes/LH type ↑/++ + Yes Death
9. 3m, M ALF Absent; 
Portal>>lobular, 
hepatic siderosis (+++)
++/+ +++, leukemia 
like, CD8/Gr B+/
Perforin+ T cells
Yes/leukemia like ↑/+ +++ Yes Death
10. 3m, M Sibling Absent; 
Portal>>lobular
++/x +++, leukemia 
like, CD8/Gr B+/
Perforin+ T cells
Yes/LH type ↑/x +++ ND Death
11. 3m, M All Present, 
Lobular>>portal; Giant 
cell hepatitis
+/+ ++, CD8/Gr B+/
Perforin+ T cells
Yes/LH type ↑/x +++ Yes Death
12. 3m, F All Present; 
Portal>>lobular; Giant 
cell hepatitis like pattern




Yes/LH type ↑/x +++ Yes




+/x +++, Leukemia 
like, CD8/Gr B+/
Perforin+ T cells
























mediated bile duct 











14. 3m, M All Absent; 
Portal>>lobular; chronic 
hepatitis like




Yes/LH type ↑/x +++ Yes Death
15. 4m, M Sibling Absent, 
Portal>>lobular; 
chronic hepatitis like
+/x +++, Leukemia 
like, CD8/Gr B+/
Perforin+ T cells
Yes/LH type ↑/x +++ Yes Death
16. 8m, F ALF Absent, centrilobular 
hemorrhage, atrophy of 
hepatic cords
++/++ ++, Storage 
histiocytic like, 
CD8/Gr B+/




↑/++ +++ Yes Death






++/+ +++; leukemia 
like, CD8/Gr B+/
Perforin+ T cells
Yes/LH type ↑/++ +++ Yes Lost
to follow-up
18. 9m, M All Absent, 
portal>>lobular




Yes/LH type ↑/++ +++ Yes Death
19. 11m, F All Absent, 
portal>>lobular
++/++ +++; leukemia 
like, CD8/Gr B+/
Perforin+ T cells























mediated bile duct 














(11 M, 16 F)
Absent; portal >>> 
lobular




Yes/LH type ↑/x + Not studied Autopsy 
series [8]
30. adults 20HLH
(19 M, 11 F)
ALF like in 
19/29
Absent; portal >>> 
lobular; hepatocyte 
necrosis (focal in 10; 
diffuse in 4), siderosis 
in 11
++/++ ++ to +++; LH 




or damage or 




↑/++ ++/+++ Not described Ref. [9]
Footnotes: d; days, m; months, M; male, F; female, C/F; clinical feature, ALF; acute liver failure, ARF; acute renal failure, GVHD; graft versus host disease, +; mild/inconspicuous, ++; moderate, +++; 
marked, x; not present, Gr. B; granzyme B, LH; lymphohistiocytic, ↑; increase in number, ND; not described, Hp; hemophagocytosis.
Table 4. 
Histopathology of liver in cases with hemophagocytic lymphohistiocytosis as described in several series (Chen et al. [10], n = 19; Ost et al. [8], n = 27; de Kerguenec et al. [9], n = 30).
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versus host disease related changes; (vii) lymphocyte depleted morphology unrelated 
to prior immunosuppressive or immunomodulator therapy; especially later in the 
course of the disease or as a part of aberrant cytokine modulation [10].
Common to all specimens and helpful in diagnosing HLH are a constellation of 
additional features that included distinctive lymphocyte-mediated bile duct injury, 
significant endothelialitis of terminal portal and central veins, sinusoidal congestion 
and dilatation, increased Kupffer cell activity with or without hemosiderosis, eryth-
rophagocytosis, and histiocytic hemophagocytosis which is reported as inconspicuous 
to florid. Steatosis and cholestasis were also usually present [8–10]. The lymphocyte-
mediated bile duct injury is characterized by nests or circumferential sheaths of 
lymphomononuclear cells interposed between the epithelium and the basal lamina 
eliciting little damage to the epithelium. The portal inflammation with cholangitis 
observed in FHL is reminiscent of primary sclerosing cholangitis, primary biliary cir-
rhosis, and vanishing bile duct syndrome; though neutrophils, plasma cells, granulo-
matous inflammation, periductal sclerosis, or ductopenia common in latter conditions 
are reported to be rare in HLH cases [10]. Endothelialitis of terminal hepatic and portal 
veins may result in transmural phlebitis and hemorrhage and extensive apoptosis of 
perivenular hepatocytes. The degree of inflammation, bile duct damage, endotheliali-
tis, cholestasis, and steatosis seem to reflect the clinical stage of the disease.
7. Liver transplantation: current concept and controversies
The mortality rate is very high in HLH associated acute liver failure cases. 
However, this association is extremely rare. Moreover, the presence of two clinical 
conditions (HLH and acute liver failure) together makes its further complicated 
and delays the diagnosis. The average time from earliest diagnosis of liver failure to 
a definitive diagnosis of HLH has been reported to be 17.27 days [23]. This suggests 
that HLH is a late occurring phenomenon in the process of ALF. On the contrary, 
there are reports which support the viewpoint of HLH causing liver injury and thus 
culminating in ALF [24, 25]. The exact mechanism is still not known, as far as HLH 
induced liver injury is concerned. It is most probably the infiltration of activated 
macrophage or over production of cytokine in HLH can explain the degree of liver 
injury. In a clinical scenario, where the patient present with prolonged fever, jaun-
dice and pancytopenia; HLH should be considered as a differential diagnosis [23]. 
The role of liver transplantation in the treatment of HLH – ALF is controversial. It is 
so, because of the primarily systemic nature of the disease, the risk of hepatic recur-
rence of HLH during the post-transplant period, increased in rejection rate and 
poor general condition of the patient to tolerate the transplant procedure [26]. The 
post-transplant survival at the end of 6 months is only 33% for the primary HLH – 
ALF patient [27]. However, a small clinical series involving nine pediatric patients, 
reported a better survival rate among the secondary HLH – ALF group [26].
In the secondary form of HLH, the liver transplantation is also not very helpful 
in the situation such as  absence of ALF (MELD score < 20–22); when the clinical 
severity is due  to the combined effect of ALF and HLH, rather than ALF alone; and 
when the HLH is severe and highly likely to be irreversible. In these situations, high 
mortality from advanced and likely irreversible HLH may limit the benefits of liver 
transplantation [28]. Liver biopsy should be performed to decide the extent of the 
liver injury and the role played by the hepatic injury vs. systemic HLH in the patients 
with ALF. However, liver transplant is still an option in HLH – ALF cases with 
predominant liver involvement from HLH and this should be undertaken before the 
highly lethal complication of HLH, such as, septic shock, DIC, bone marrow failure, 
explosive immune activation from HLH supervenes.
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